LCM
ATRA icon

Landscape Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Landscape Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-509
Closed -$336K – 573
2015
Q4 		$336K Buy
+509
New +$385K 0.04% 650

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Landscape Capital Management's ATRA Position: Q1 2016 in Review

Landscape Capital Management sold out of Atara Biotherapeutics (ATRA) in Q1 2016, closing a stake of 509 shares — an estimated $336K sold.

Landscape Capital Management first reported a position in ATRA in Q4 2015 and held it in 1 quarter. The position peaked at $336K in Q4 2015. 71 funds tracked by Wall St. Rank hold ATRA as of Q1 2016.

  • Landscape Capital Management reported no remaining Atara Biotherapeutics position as of Q1 2016 after selling out during the quarter.
  • Landscape Capital Management sold 509 Atara Biotherapeutics shares in Q1 2016, an estimated $336K.
  • Landscape Capital Management first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 1 quarter.
  • Landscape Capital Management's Atara Biotherapeutics position peaked at $336K in Q4 2015.
  • 71 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2016.

Based on Landscape Capital Management's 13F filing for Q1 2016, filed 11 May 2016.